Small intestinal bacterial overgrowth in inactive Crohn’s disease: Influence of thiopurine and biological treatment

Table 1 Baseline characteristics of the patients n (%)

Time since disease diagnosis (yr)	8.5 ± 7.3
Age (yr)	40.8 ± 12.1
Gender (% female)	56 (52.3)
BMI (kg/m2)	25.2 ± 4.9
Location
Ileum	39 (36.5)
Ileum and colon	53 (49.5)
Colon	15 (14)
Pattern
Inflammatory	29 (27.1)
Stenotic	58 (54.2)
Fistulizing	20 (18.7)
Ileocecal valve resection	63 (58.9)
Treatment
Immunosuppressant1	62 (57.9)
Biological treatment2	21 (19.6)
Double (immunosuppressant + biological)	13 (12.1)
Proton pump inhibitors	19 (17.8)
Bacterial overgrowth	18 (16.8)
Presence of symptoms (n = 102)	55 (51.4)
Bowel frequency (24 h)	2.8 ± 2

¹Fifty-six azathioprine, six mercaptopurine;

²Seventeen infliximab, four adalimumab. Quantitative variables are expressed as mean ± SD.